HeartSciences Inc. Warrant - HSCSW STOCK NEWS

HeartSciences extends distribution channel through new agreement with MedPhy Technologies in India.

HeartSciences signs distribution agreement with FJ Medical for Nordic countries

HeartSciences' MyoVista wavECGTM selected for heart screening evaluation study in Ireland, potentially leading to national rollout

HeartSciences, an AI-based medical technology company, has been issued a notice of patent allowance from the European Patent Office. The patent covers quantification by an ECG of key echocardiographic measures of heart function using AI methods. HeartSciences has been granted or allowed 41 patents, including 9 in the United States, and has international coverage across key countries. The addition of cardiac dysfunction detection to the ECG is expected to provide significant benefit to healthcare providers and health systems worldwide. The company's MyoVista® could play a significant role in heart health screening globally. The patent further expands HeartSciences' extensive patent portfolio, providing a major competitive advantage as they move toward commercialization.

HeartSciences announces that its MyoVista wavECG has been selected for commercial use in clinical practice by the Naya Imaging Center in Denmark. The center will provide cardiac testing using MyoVista, focusing on preventative screening and diagnostics. The MyoVistas in Denmark are prior device versions covered by CE mark, and the company intends to update the CE mark under the new EU Medical Device Regulation.

HeartSciences, an AI-based medical technology company, provided a business update and reported financial results for the fiscal year ended April 30, 2023. Key milestones include completing patient enrollment for the MyoVista wavECG multi-center pivotal study, expanding the IP portfolio, receiving patents for AI and key aspects of MyoVista Technology, and entering into a collaboration with Rutgers University for AI ECG algorithm development. The American Medical Association issued new reimbursement codes for AI ECG risk assessment. The company also strengthened its balance sheet and board of directors.

HeartSciences, an AI-based medical technology company, has been recognized as a top healthcare artificial intelligence solutions provider by Healthcare Tech Outlook Magazine. The recognition highlights the company's MyoVista device, which uses AI to transform ECGs/EKGs for earlier detection of heart disease. The company recently completed patient enrollment for its FDA pivotal study and plans to make an FDA submission later this year. HeartSciences aims to become a fixture in frontline healthcare to help physicians make better referral decisions for at-risk patients.

HeartSciences completes patient enrollment for FDA De Novo submission of MyoVista wavECG pivotal study. The study aims to validate the diagnostic performance of the MyoVista AI algorithm for the detection of impaired left ventricular relaxation. Data will now undergo verification and analysis.